B. Riley analyst issues BUY recommendation for PGEN on September 25, 2026 01:07AM ET. PGEN was trading at $7.7 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 11 - Buy, 4 - Hold, 1 - Sell recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when posted...
Key Points - Multiple law firms have filed class action lawsuits against Capricor Therapeutics, Inc. for...
Vaxart, Inc. (VXRT) is currently $0.4798 — here's the support-and-resistance map drawn from swing pivots, volume...
Nektar Therapeutics (NKTR) gives both camps something to hold. These are the 5 bullish and 7...
AXT, Inc. (AXTI) gives both camps something to hold. These are the 8 bullish and 6...
from HSBC issued a price target of $38.00 for LIFE on 2026-09-24 09:59:00.The adjusted price target was set to $38.00.At the time of the announcement, LIFE was trading at $33.91.The...
from Goldman Sachs issued a price target of $36.00 for KOD on 2026-09-24 08:48:07.The adjusted price target was set to $36.00.At the time of the announcement, KOD was trading at...
Andrea Newkirk from Goldman Sachs issued a price target of $7.00 for SGMT on 2026-09-24 08:37:23.The adjusted price target was set to $7.00.At the time of the announcement, SGMT was...
from RBC Capital issued a price target of $62.00 for BSVN on 2026-09-23 12:39:00.The adjusted price target was set to $62.00.At the time of the announcement, BSVN was trading at...
from Wedbush issued a price target of $50.00 for NKTR on 2026-09-23 11:45:04.The adjusted price target was set to $50.00.At the time of the announcement, NKTR was trading at $60.97.The...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
